Conjugates for the treatment of mesothelioma
AssigneeMolMed SpA
InventorsClaudio Bordignon, Antonio Lambiase
Life of this patent
Estimating the term…
Abstract
The present invention provides conjugates of cytokines and targeting peptides that is able to bind to a receptor expressed on tumor-associated vessels or to a component of the extracellular matrix associated to the tumor vessels, for treatment of malignant pleural mesothelioma. In particular, the invention provides conjugates comprising the cytokine TNF linked to a peptide containing the NGR motif. The invention further provides pharmaceutical compositions comprising such conjugate and pharmaceutical formulations comprising conjugates dissolved in appropriate buffers.
Claims11
A method for treating mesothelioma in a patient comprising administering to a patient suffering from mesothelioma a conjugate comprising a targeting peptide and a cytokine, wherein the targeting peptide is a peptide containing a NGR motif and wherein the cytokine is TNFα.
A method for treating mesothelioma in a patient comprising administering to a patient suffering from mesothelioma a pharmaceutical composition comprising an effective amount of a conjugate comprising a targeting peptide and a cytokine, wherein the targeting peptide is a peptide containing a NGR motif and wherein the cytokine is TNFα together with pharmaceutically acceptable carriers and diluents.
Dependencies are inferred from the claim text.